Similarly, for the LY3009120-resistant equine melanoma cell line (eRGO6), the cause of resistance may be due to its accompanying molecular alterations, like the loss of tumor suppressor genes such as the TP35, PTEN, CDKN2A, RB1, SPARC, and PI3K/AKT pathway mutations, alterations in cell translational machinery (cytosolic ribosomal proteins (rProteins)) [35], and the dysregulation of the metabolism (HMOX1) [36]. This evidence concerns the gene CDKN2A and melanoma.